|Bid||36.62 x 2900|
|Ask||37.26 x 800|
|Day's Range||36.82 - 37.29|
|52 Week Range||28.13 - 39.96|
|Beta (3Y Monthly)||-0.09|
|PE Ratio (TTM)||26.38|
|Forward Dividend & Yield||0.29 (0.78%)|
|1y Target Est||28.03|
Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.
Dr. Reddy’s Laboratories Ltd announced that the Company will be presenting at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.
The Zacks Analyst Blog Highlights: Internet Initiative Japan, Sony, Ingersoll-Rand, HDFC Bank and Dr. Reddy's Laboratories
The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.
Highlighted as Zacks Bull and Bear of the Day Dr. Reddy???s Laboratories, Dillard???s, Facebook, Netflix and Amazon
Dr. Reddy’s Laboratories Ltd. today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela for Oral Suspension, approved by the U.S.
Dr. Reddy’s Laboratories Ltd , along with its subsidiaries together referred to as “Dr. Reddy’s”, today announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox Capsules in the United States market from the U.S.
The Dow Jones Industrial Average gained 0.35 percent to close at 23,675.64, while the S&P 500 Index increased 0.01 percent to close at 2,546.16. The Nasdaq Composite Index climbed 0.45 percent to close at 6,783.91.
Zacks.com featured highlights include: Abercrombie, Dr. Reddy???s, Cree, Otter and Shenandoah
The last few years for drug-maker Teva Pharmaceuticals (NASDAQ:TEVA) haven’t exactly been that wonderful. TEVA stock has plunged on a series of mishaps and issues. In fact, TEVA has fallen enough that America’s favorite value investor, Warren Buffett, has taken a huge interest in the stock over the last few quarters.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry.
Dr. Reddy’s Laboratories Ltd. announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter store-brand equivalent of Prilosec® OTC Tablets, 20 mg, in the United States market as approved by the U.S.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing. The case now involves at least 16 companies and 300 drugs, the report said, citing Joseph Nielsen, an assistant attorney general and antitrust investigator in Connecticut, who has been a leader in the probe. Nielsen is quoted as saying, "this is most likely the largest cartel in the history of the United States." The victims were consumers and taxpayers, who have been carrying the high cost of overcharges on common antiboitics, blood-pressure medications, arthritis treatments, anxiety pills and more, said the report. Teva Pharmaceuticals Industries Ltd. ADRs fell 5.7% on the news. Mylan NV was down 4.6%, and Dr. Reddy Labs Ltd was down 3%. Abbott Labs was down 1.4% and Pfizer Inc. was down 1.6%. The S&P 500 was down 1.8% and the Dow Jones Industrial Average was down about 2%.
NEW YORK, Dec. 10, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The stock market has certainly seen its share of volatility in recent months. Sure, the broader S&P 500 (SPX) is down about 8% from Oct. 1, and it has been a pretty wild ride both up and down across the last two months or so. Equally ugly lately has been Apple Inc. (AAPL) which has shed more than 22% since Oct. 1.
Continuous innovation and research in the field of biotechnology and an increasingly aged population in the United States are helping whet appetite for healthcare shares.
Zacks.com highlights: Marcus, Papa Murphy's Holdings, Dr. Reddy's Laboratories, Tesla and Spirit Airlines